GBM
MCID: GLB015
MIFTS: 60

Glioblastoma Multiforme (GBM)

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 75 55 6 15 17 72
Glioblastoma 44 72
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 72
Adult Glioblastoma 72
Gbm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3068
MeSH 44 D005909
SNOMED-CT 68 63634009
UMLS 72 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma Multiforme

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to giant cell glioblastoma and glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Phospholipase-C Pathway and PI3K-Akt signaling pathway. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 75 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 887)
# Related Disease Score Top Affiliating Genes
1 giant cell glioblastoma 34.0 TP53 PTEN MGMT IDH1 EGFR
2 glioblastoma 33.3 TP53 PTEN PDGFRA MTOR MIR221 MIR21
3 brain cancer 32.6 TP53 PTEN PDGFRA MGMT IDH1 EGFR
4 grade iii astrocytoma 32.6 TP53 PTEN PDGFRA MGMT EGFR
5 gliosarcoma 32.2 TP53 PTEN MGMT IDH1 EGFR
6 glioma 32.1 TP53 PTEN PDGFRA MIR328 MIR221 MIR210
7 oligodendroglioma 32.0 TP53 PTEN PDGFRA MGMT IDH1 EGFR
8 brain glioma 31.9 TP53 MGMT IDH1 EGFR
9 medulloblastoma 31.9 TP53 PTEN PDGFRA MGMT IDH1 EGFR
10 fibrillary astrocytoma 31.9 TP53 MGMT IDH1
11 pleomorphic xanthoastrocytoma 31.9 TP53 MGMT IDH1
12 gliomatosis cerebri 31.8 TP53 PTEN IDH1 EGFR
13 mixed glioma 31.7 TP53 PDGFRA IDH1
14 li-fraumeni syndrome 31.5 TP53 PTEN IDH1 EGFR
15 small cell carcinoma 31.5 TP53 PTEN PDGFRA EGFR
16 anaplastic oligodendroglioma 31.4 MGMT EGFR
17 spinal cord astrocytoma 31.3 TP53 MGMT IDH1
18 brain stem glioma 31.3 TP53 IDH1 EGFR
19 cerebellar astrocytoma 31.2 TP53 IDH1
20 central nervous system cancer 31.2 TP53 PTEN MGMT IDH1 EGFR
21 nervous system cancer 31.2 TP53 PTEN MGMT IDH1 EGFR
22 gastrointestinal stromal tumor 31.2 TP53 PTEN PDGFRA EGFR
23 supratentorial cancer 31.2 TP53 PTEN PDGFRA MGMT IDH1 EGFR
24 thymoma 31.0 TP53 MTOR EGFR AKT3
25 small cell cancer of the lung 31.0 TP53 PTEN MIR21 EGFR
26 intrahepatic cholangiocarcinoma 30.9 TP53 IDH1 EGFR
27 malignant peripheral nerve sheath tumor 30.9 TP53 PDGFRA EGFR
28 intracranial chondrosarcoma 30.8 TP53 IDH1
29 cholangiocarcinoma 30.6 TP53 PTEN MTOR MIR21 IDH1 EGFR
30 oral cancer 30.5 TP53 MIR21 EGFR
31 testicular germ cell tumor 30.1 TP53 PTEN MIR133B
32 pituitary adenoma 30.0 MIR149 MIR132 MIR128-1
33 leukemia, acute lymphoblastic 29.9 MIR221 MIR210 MIR21 MIR155 MIR128-1
34 gastric cancer 29.7 TP53 PTEN MIR221 MIR21 MGMT EGFR
35 muscular dystrophy, duchenne type 29.7 MIR221 MIR210 MIR21
36 kidney cancer 29.7 TP53 MTOR MIR210 MIR21 MIR185
37 ovarian cancer 29.6 TP53 PTEN MIR221 MIR210 MIR21 MIR155
38 prostate cancer 29.6 TP53 PTEN MTOR MIR221 MIR210 MIR21
39 follicular lymphoma 29.5 MIR210 MIR155 MIR149
40 pancreatic cancer 29.5 TP53 MTOR MIR221 MIR210 MIR21 MIR155
41 bladder cancer 29.3 TP53 MIR221 MIR21 MIR185 MIR133B EGFR
42 squamous cell carcinoma, head and neck 29.1 TP53 PTEN MIR221 MIR210 MIR21 MIR155
43 diffuse large b-cell lymphoma 28.7 TP53 MIR328 MIR221 MIR210 MIR21 MIR155
44 leukemia, acute myeloid 28.6 TP53 MTOR MIR328 MIR221 MIR210 MIR21
45 breast cancer 28.2 TP53 PTEN MTOR MIR328 MIR221 MIR210
46 hepatocellular carcinoma 27.9 TP53 PTEN MTOR MIR221 MIR21 MIR185
47 colorectal cancer 27.7 TP53 PTEN MTOR MIR328 MIR221 MIR21
48 melanoma 27.6 TP53 PTEN MIR323A MIR221 MIR210 MIR185
49 lung cancer 27.6 TP53 PTEN MIR221 MIR210 MIR21 MIR185
50 brain glioblastoma multiforme 12.7

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 EGFR IDH1 MGMT MTOR PDGFRA PTEN

Drugs & Therapeutics for Glioblastoma Multiforme

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 616)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
6
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Trioxsalen Approved Phase 3 3902-71-4 5585
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Streptozocin Approved, Investigational Phase 2, Phase 3 18883-66-4 29327
13
Iodine Approved, Investigational Phase 3 7553-56-2 807
14
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
15
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
16
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Etoposide Approved Phase 3 33419-42-0 36462
19
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
20
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
21
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
22
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Povidone Approved Phase 3 9003-39-8
25
Povidone-iodine Approved Phase 3 25655-41-8
26
Flucytosine Approved, Investigational Phase 2, Phase 3 2022-85-7 3366
27
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
28
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
29
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
30
Carmustine Approved, Investigational Phase 3 154-93-8 2578
31
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
32
Histamine Approved, Investigational Phase 3 51-45-6 774
33
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
34
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
35
Norepinephrine Approved Phase 3 51-41-2 439260
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
39
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
40
Rindopepimut Investigational Phase 3 1108208-65-6
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42
Semustine Experimental, Investigational Phase 2, Phase 3 13909-09-6
43
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
44 Dianhydrogalactitol Investigational Phase 3 23261-20-3
45 Antiparkinson Agents Phase 2, Phase 3
46 Serine Proteinase Inhibitors Phase 3
47 Parasympatholytics Phase 2, Phase 3
48 Muscarinic Antagonists Phase 2, Phase 3
49 Cholinergic Antagonists Phase 2, Phase 3
50 Dihematoporphyrin Ether Phase 3

Interventional clinical trials:

(show top 50) (show all 1512)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
5 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
6 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
8 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Unknown status NCT01805453 Phase 3 Losartan;Placebo
9 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
10 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
11 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
12 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
13 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
14 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
15 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
16 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
17 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
18 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
19 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
20 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
21 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
22 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
23 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
24 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
25 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
26 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
27 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
28 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
29 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
30 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
31 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
32 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
33 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
34 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
35 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
36 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
37 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
38 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
39 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
40 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
41 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
42 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
43 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
44 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
46 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
47 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
48 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
49 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
50 A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) Recruiting NCT02685605 Phase 3 Temozolomide

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine
Temozolomide

Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

41
Brain, T Cells, Endothelial, Testes, Breast, Lung, Spinal Cord

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 30333)
# Title Authors PMID Year
1
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 9 38 88
18577219 2008
2
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 38 88
19559015 2009
3
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 38 88
18759060 2009
4
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 9 38
19937796 2010
5
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 9 38
20428809 2010
6
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 9 38
20467331 2010
7
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 9 38
20195615 2010
8
FasL gene knock-down therapy enhances the antiglioma immune response. 9 38
20406899 2010
9
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. 9 38
20462843 2010
10
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 9 38
20412570 2010
11
Promising human brain tumors therapy with interference RNA intervention (iRNAi). 9 38
20118657 2010
12
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 9 38
20127563 2010
13
Evaluation of the prognostic value of CD44 in glioblastoma multiforme. 9 38
20150644 2010
14
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. 9 38
20150362 2010
15
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. 9 38
20150365 2010
16
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. 9 38
19996278 2009
17
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. 9 38
19931733 2009
18
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. 9 38
19861406 2009
19
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. 9 38
19164435 2009
20
A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. 9 38
19808964 2009
21
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. 9 38
19637364 2009
22
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. 9 38
19658181 2009
23
Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. 9 38
19996130 2009
24
Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. 9 38
19723667 2009
25
MGMT promoter hypermethylation in a series of 104 glioblastomas. 9 38
19656999 2009
26
The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. 9 38
19601750 2009
27
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. 9 38
18952979 2009
28
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. 9 38
19412429 2009
29
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas. 9 38
19587465 2009
30
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 9 38
19346643 2009
31
Activation of telomerase by human cytomegalovirus. 9 38
19318640 2009
32
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. 9 38
19011762 2009
33
Tyrosine phosphorylation and CD95: a FAScinating switch. 9 38
19221505 2009
34
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. 9 38
19293809 2009
35
Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. 9 38
19141386 2009
36
Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. 9 38
19074142 2009
37
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 9 38
19657395 2009
38
Significance of p53 and CD31 in astrogliomas. 9 38
18821037 2009
39
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. 9 38
18991494 2009
40
Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. 9 38
18940813 2008
41
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. 9 38
18955445 2008
42
Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib. 9 38
19189656 2008
43
The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. 9 38
18976073 2008
44
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. 9 38
18400046 2008
45
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. 9 38
18708058 2008
46
Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. 9 38
18677408 2008
47
CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. 9 38
18812968 2008
48
Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44. 9 38
19024103 2008
49
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. 9 38
18757412 2008
50
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. 9 38
18665158 2008

Variations for Glioblastoma Multiforme

ClinVar genetic disease variations for Glioblastoma Multiforme:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SLX4 NM_032444.4(SLX4): c.859_860del (p.Ser287fs) deletion Likely pathogenic 16:3652209-3652210 16:3602208-3602209

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 TP53 PTEN PDGFRA MTOR EGFR AKT3
2
Show member pathways
12.91 TP53 PTEN PDGFRA MTOR EGFR AKT3
3
Show member pathways
12.88 TP53 PTEN PDGFRA MTOR EGFR AKT3
4
Show member pathways
12.79 PTEN PDGFRA MTOR EGFR AKT3
5
Show member pathways
12.75 TP53 PTEN PDGFRA MTOR EGFR AKT3
6 12.71 TP53 PTEN PDGFRA MTOR EGFR AKT3
7
Show member pathways
12.68 TP53 PTEN MTOR EGFR AKT3
8
Show member pathways
12.57 TP53 PTEN PDGFRA MTOR EGFR AKT3
9
Show member pathways
12.55 TP53 PTEN PDGFRA MTOR EGFR AKT3
10
Show member pathways
12.51 TP53 MTOR EGFR AKT3
11
Show member pathways
12.33 PDGFRA MTOR EGFR AKT3
12
Show member pathways
12.33 PDGFRA MTOR EGFR AKT3
13
Show member pathways
12.32 TP53 PTEN MTOR AKT3
14
Show member pathways
12.31 TP53 PDGFRA MTOR EGFR AKT3
15
Show member pathways
12.31 TP53 PTEN PDGFRA MTOR EGFR AKT3
16
Show member pathways
12.3 TP53 PTEN MIR221 MIR210
17 12.11 TP53 MTOR MIR21 EGFR AKT3
18 12.08 TP53 PTEN MTOR AKT3
19 12.06 TP53 PTEN MTOR EGFR
20
Show member pathways
12.04 PTEN PDGFRA EGFR AKT3
21
Show member pathways
12.01 PTEN MTOR EGFR AKT3
22
Show member pathways
11.98 TP53 PTEN PDGFRA MTOR EGFR AKT3
23 11.89 TP53 PTEN PDGFRA MTOR EGFR AKT3
24 11.89 TP53 PTEN PDGFRA MTOR MIR221 MIR210
25 11.87 TP53 PTEN MTOR
26 11.87 MTOR EGFR AKT3
27 11.79 TP53 PTEN AKT3
28 11.75 TP53 PTEN PDGFRA MTOR MGMT EGFR
29
Show member pathways
11.66 TP53 MTOR AKT3
30 11.66 TP53 PTEN MTOR AKT3
31 11.48 TP53 PDGFRA EGFR
32 11.46 TP53 MIR221 MIR210
33 11.34 TP53 PTEN PDGFRA MTOR IDH1 EGFR
34 11.32 PDGFRA MTOR EGFR AKT3
35 11.29 MIR221 MIR133B MIR128-1

GO Terms for Glioblastoma Multiforme

Cellular components related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR328 MIR323A MIR221 MIR210 MIR21 MIR185
2 PML body GO:0016605 9.13 TP53 PTEN MTOR

Biological processes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.98 TP53 PTEN MIR221 MIR21 MIR137
2 negative regulation of gene expression GO:0010629 9.96 MIR21 MIR185 MIR155 MIR132
3 positive regulation of protein phosphorylation GO:0001934 9.92 MTOR MIR21 MIR128-1 EGFR
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 PTEN PDGFRA MIR221 MIR21 EGFR
5 negative regulation of apoptotic process GO:0043066 9.88 TP53 PTEN MIR221 MIR21 MGMT EGFR
6 positive regulation of angiogenesis GO:0045766 9.87 MIR210 MIR21 MIR132 AKT3
7 wound healing GO:0042060 9.84 PDGFRA MTOR EGFR
8 response to organic cyclic compound GO:0014070 9.84 PTEN MGMT IDH1 EGFR
9 positive regulation of inflammatory response GO:0050729 9.83 MIR21 MIR155 EGFR
10 negative regulation of cell migration GO:0030336 9.83 PTEN MIR21 MIR149 MIR137
11 cellular response to amino acid stimulus GO:0071230 9.79 PDGFRA MTOR EGFR
12 positive regulation of fibroblast proliferation GO:0048146 9.77 PDGFRA MIR155 EGFR
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.77 MIR221 MIR210 AKT3
14 positive regulation of epithelial to mesenchymal transition GO:0010718 9.75 MTOR MIR221 MIR21
15 cholesterol homeostasis GO:0042632 9.73 MIR185 MIR155 MIR132 MIR128-1
16 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.72 PTEN MIR185 MIR137
17 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR185 MIR155
18 positive regulation of myotube differentiation GO:0010831 9.67 MTOR MIR133B
19 platelet-derived growth factor receptor signaling pathway GO:0048008 9.67 PTEN PDGFRA MIR221
20 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 PTEN MIR21 MIR137 MIR133B
21 regulation of protein kinase B signaling GO:0051896 9.65 MTOR MIR21
22 negative regulation of cell size GO:0045792 9.65 PTEN MTOR
23 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.65 PTEN MIR221 MIR21 MIR185 MIR133B
24 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 TP53 EGFR
25 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR210 MIR21
26 positive regulation of vascular endothelial cell proliferation GO:1905564 9.63 MIR21 MIR132 AKT3
27 positive regulation of protein kinase B signaling GO:0051897 9.63 PDGFRA MTOR MIR221 MIR21 MIR132 EGFR
28 negative regulation of blood vessel endothelial cell migration GO:0043537 9.62 MIR155 MIR137 MIR133B MIR132
29 negative regulation of regulatory T cell differentiation GO:0045590 9.61 MIR21 MIR155
30 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.61 MIR221 MIR155
31 negative regulation of cell adhesion molecule production GO:0060354 9.56 MIR221 MIR155
32 positive regulation of wound healing, spreading of epidermal cells GO:1903691 9.51 MTOR MIR221
33 miRNA mediated inhibition of translation GO:0035278 9.43 MIR221 MIR210 MIR21 MIR155 MIR133B MIR132
34 gene silencing by miRNA GO:0035195 9.4 MIR328 MIR323A MIR221 MIR210 MIR21 MIR185
35 positive regulation of cell proliferation GO:0008284 10.06 PTEN PDGFRA MIR21 MIR132 EGFR
36 negative regulation of cell proliferation GO:0008285 10.04 TP53 PTEN MIR221 MIR21 MIR137
37 positive regulation of gene expression GO:0010628 10.03 TP53 PTEN MTOR MIR21 MIR132

Molecular functions related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR328 MIR221 MIR210 MIR21 MIR185 MIR155
2 platelet-derived growth factor receptor binding GO:0005161 8.96 PTEN PDGFRA

Sources for Glioblastoma Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....